Takeda Pharmaceutical Co., Ltd./ JP3463000004 /
| 2024-11-07 3:30:00 PM | Chg. -1.8400 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 26.7600USD | -6.43% | 119,689 Turnover: 7,599.8400 |
-Bid Size: - | -Ask Size: - | 43.47 bill.USD | - | - |
Assets
|
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
2024 IFRS in mill. JPY |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 1.39 mill. | 1.45 mill. | 1.58 mill. | 1.69 mill. | 1.99 mill. | ||||||
| Intangible Assets | 4.17 mill. | 3.91 mill. | 3.82 mill. | 4.27 mill. | 4.27 mill. | ||||||
| Long-Term Investments | 262,121 | 235,882 | 96,579 | 99,174 | 89,831 | ||||||
| Fixed Assets | - | - | 10.58 mill. | 11.56 mill. | 12.55 mill. | ||||||
| Inventories | 759,599 | 753,881 | 853,167 | 986,457 | 1.21 mill. | ||||||
| Accounts Receivable | 757,005 | 783,091 | 696,644 | 649,429 | 668,403 | ||||||
| Cash and Cash Equivalents | 637,614 | 966,222 | 849,695 | 533,530 | 457,800 | ||||||
| Current Assets | 2.47 mill. | 2.71 mill. | 2.59 mill. | 2.4 mill. | 2.56 mill. | ||||||
| Total Assets | 12.82 mill. | 12.91 mill. | 13.18 mill. | 13.96 mill. | 15.11 mill. | ||||||
Liabilities
|
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
2024 IFRS in mill. JPY |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 318,816 | 343,838 | 516,297 | 649,233 | 547,521 | ||||||
| Long-term debt | - | - | 4.14 mill. | 4.04 mill. | 4.48 mill. | ||||||
| Liabilities to Banks | 586,817 | 22,153 | - | - | - | ||||||
| Provisions | 930,490 | 726,803 | 947,212 | 834,949 | 652,570 | ||||||
| Liabilities | 8.09 mill. | 7.74 mill. | 7.49 mill. | 7.6 mill. | 7.83 mill. | ||||||
| Share Capital | 1.67 mill. | 1.67 mill. | - | - | - | ||||||
| Total Equity | 4.73 mill. | 5.18 mill. | 5.68 mill. | 6.35 mill. | 7.27 mill. | ||||||
| Minority Interests | 4,003 | 4,140 | 504 | 549 | 741 | ||||||
| Total liabilities equity | 12.82 mill. | 12.91 mill. | 13.18 mill. | 13.96 mill. | 15.11 mill. | ||||||
Income Statement
|
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
2024 IFRS in mill. JPY |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 3.29 mill. | 3.2 mill. | 3.57 mill. | 4.03 mill. | 4.26 mill. | ||||||
| Depreciation (total) | 455,420 | 421,864 | 472,915 | 542,443 | 652,117 | ||||||
| Operating Result | 100,408 | 509,269 | 460,844 | 490,505 | 214,075 | ||||||
| Interest Income | -137,175 | -143,110 | -142,907 | -106,785 | -167,757 | ||||||
| Income Before Taxes | -60,754 | 366,235 | - | - | - | ||||||
| Income Taxes | -105,044 | -9,936 | 72,405 | 58,052 | -91,406 | ||||||
| Minority Interests Profit | -49 | -166 | -107 | -21 | 130 | ||||||
| Net Income | 44,241 | 376,005 | 230,059 | 317,017 | 144,067 | ||||||
Per Share
Cash Flow
|
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
2024 IFRS in mill. JPY |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 669,752 | 1.01 mill. | 1.12 mill. | 977,156 | 716,344 | ||||||
| Cash Flow from Investing Activities | 292,119 | 393,530 | -198,125 | -607,102 | -463,862 | ||||||
| Cash Flow from Financing | -1.01 mill. | -1.09 mill. | -1.07 mill. | -709,148 | -354,416 | ||||||
| Decrease / Increase in Cash | -43,342 | 316,107 | - | - | - | ||||||
| Employees | 47,495 | 47,099 | 47,000 | 47,347 | - | ||||||
